相关实验视频
Updated: May 20, 2025

03:25
Simple Continuous Glucose Monitoring in Freely Moving Mice
Published on: February 24, 2023
5.1K
机器学习驱动的D-葡萄糖预测使用一种用于非侵入性糖尿病管理的新型生物传感器
Pardis Sadeghi1, Shahriar Noroozizadeh2,3, Rania Alshawabkeh1
1Electrical & Computer Engineering, W.M. Keck Laboratory for Integrated Ferroics, Northeastern University, Boston, MA 02115, USA.
Biosensors
|March 26, 2025
概括
这项研究引入了一种新的非侵入性糖尿病监测系统,使用生物传感器和机器学习来检测呼吸中的D-葡萄糖. 先进的框架准确地分类葡萄糖水平,改善糖尿病护理.
科学领域:
- 生物医学工程 生物医学工程
- 分析化学 分析化学
- 机器学习 机器学习
背景情况:
- 非侵入性糖尿病监测对于电子医疗保健至关重要,但面临着计算和准确性挑战.
- 目前在呼出的气凝液/气溶中检测葡萄糖的方法是有限的.
- 需要可靠,高效和准确的葡萄糖监测系统.
研究的目的:
- 开发一种非侵入式的糖尿病诊断和监测系统,使用呼出的呼吸进行监测.
- 将机器学习与分子印记聚合物生物传感器集成,用于检测D-葡萄糖.
- 提高糖尿病监测中的预测准确性和计算效率.
主要方法:
- 使用分子印记的聚合物生物传感器来检测D-葡萄糖在呼出的气凝液/气溶中.
- 使用先进的机器学习模型 (卷积神经网络,循环神经网络) 来进行信号分析.
- 实施合成数据生成技术 (合成少数群体过量采样技术,生成对抗网络) 来应对数据挑战.
主要成果:
- 从呼出的气息中获得临床相关的D-葡萄糖水平的准确分类.
- 证明了将生物传感器与先进机器学习集成为非侵入性葡萄糖监测的有效性.
- 成功解决了数据不平衡,样本有限以及传感器间可变性问题.
结论:
- 开发的框架为糖尿病监测提供了一个有希望的非侵入性方法.
- 生物传感器和机器学习的整合提高了葡萄糖检测的准确性和效率.
- 这项技术有可能显著改善糖尿病管理和电子医疗保健.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Hypoglycemia and Glucagon
143
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
143
Diabetes: Symptoms, Diagnosis, and Complications
494
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
494
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Glucagon-like Receptor Agonists
277
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
277
Diabetes: Management and Pharmacotherapy
216
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
216

